Form 8-K - Current report:
SEC Accession No. 0001493152-25-022631
Filing Date
2025-11-14
Accepted
2025-11-14 09:05:50
Documents
14
Period of Report
2025-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 39412
2 EX-99.1 ex99-1.htm EX-99.1 17923
3 GRAPHIC ex99-1_001.jpg GRAPHIC 7284
  Complete submission text file 0001493152-25-022631.txt   238780

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE gtbp-20251114.xsd EX-101.SCH 3023
5 XBRL LABEL FILE gtbp-20251114_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE gtbp-20251114_pre.xml EX-101.PRE 22364
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3681
Mailing Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111
Business Address 505 MONTGOMERY STREET 10TH FLOOR SAN FRANCISCO CA 94111 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

EIN.: 941620407 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40023 | Film No.: 251481678
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)